<DOC>
	<DOC>NCT02221830</DOC>
	<brief_summary>Evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (PE)</brief_summary>
	<brief_title>Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)</brief_title>
	<detailed_description>The overall goal of this study is to evaluate the efficacy of postpartum 24 hour oxytocin infusion as a prevention-oriented strategy to reduce blood loss in patients with pre-eclampsia (PE) in a blinded, placebo controlled, randomized controlled trial.</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1. vaginal or cesarean delivery at a gestational age greater than or equal to 20 weeks gestational age; 2. diagnosis of preeclampsia (PE defined using standard definitions based on the ACOG bulletin and the NIH Working Group on High Blood Pressure in Pregnancy (i.e., a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg on at least 2 occasions at least 6 hours apart after 20 weeks gestation and proteinuria of &gt; 300mg per 24 hour period or &gt; 1+ on dipstick). 3. patients treated with magnesium sulfate for 24 hours post partum at 2g/hr (standard of care when deemed appropriate by clinician for seizure prophylaxis) 1. abnormal placentation (previa, accreta, etc) 2. antenatal hemorrhage 3. contraindication to oxytocin</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>